Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 12/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glenvastatin SCHEMBL1040745 | 1.00 | HMGCR (1.00) | HMGCR | |
| Glenvastatin SCHEMBL29557142 | 1.00 | HMGCR (1.00) | HMGCR | |
| Glenvastatin SCHEMBL1040744 | 1.00 | HMGCR (1.00) | HMGCR | |
| Glenvastatin SCHEMBL9872411 | 1.00 | HMGCR (1.00) | HMGCR | |
| SCHEMBL9022892 | 1.00 | HMGCR (1.00) | HMGCR | |
| Glenvastatin SCHEMBL1660022 | 1.00 | HMGCR (1.00) | HMGCR | |
| Glenvastatin SCHEMBL10024037 | 1.00 | HMGCR (1.00) | HMGCR | |
| SCHEMBL9527887 | 0.96 | HMGCR (1.00) | HMGCR | |
| SCHEMBL9022328 | 0.94 | HMGCR (0.89) | HMGCR | |
| SCHEMBL9023237 | 0.92 | HMGCR (0.85) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| US-20210085695-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MIGRAINE HEADACHES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2021-03-25 | — | — | US | claimed |
| US-20200129440-A1 | COMPLEX FORMULATION COMPRISING HMG-COA REDUCTASE INHIBITOR AND CLOPIDOGREL | DONG WHA PHARM. CO., LTD. (KR) | 2020-04-30 | — | — | US | claimed |
| EP-2809319-B1 | IMPROVEMENTS IN TEAR FILM STABILITY | UNIV SYDNEY (AU) | 2018-04-18 | — | — | EP | claimed |
| EP-2813509-B1 | 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c]isoquinoline derivatives | ASTRAZENECA AB (SE) | 2017-02-01 | — | — | EP | claimed |
| EP-2521453-B1 | COMBINATIONS OF VITAMIN D AND A STATIN FOR THE TREATMENT OF MIGRAINE HEADACHES | BETH ISRAEL HOSPITAL (US) | 2016-05-11 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20150094447-A1 | Novel Nitric Oxide Synthase Agonist Polymers | PALMETTO PHARMACEUTICALS LLC (US) | 2015-04-02 | — | — | US | claimed |
| US-8936635-B2 | Bioresorbable nitric oxide agonist prodrug scaffolds for vascular stents | PALMETTO PHARMACEUTICALS LLC (US) | 2015-01-20 | — | — | US | claimed |
| EP-2813509-A1 | 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4,3-c]isoquinoline derivatives | Takeda GmbH (DE) | 2014-12-17 | — | — | EP | claimed |
| EP-1505986-A1 | COMBINATION OF AN HMG-CoA REDUCTASE INHIBITOR AND A NITRATE ESTER | Scaramuzzino, Giovanni (IT) | 2005-02-16 | — | — | EP | claimed |
| US-20040248972-A1 | Compounds and uses thereof | AMBIT BIOSCIENCES CORPORATION | 2004-12-09 | — | — | US | claimed |
| WO-2004103960-A2 | COMPOUNDS AND USES THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2004-12-02 | — | — | WO | claimed |
| US-20040053842-A1 | Methods of treatment with CETP inhibitors and antihypertensive agents | PFIZER INC. | 2004-03-18 | — | — | US | claimed |
| US-20040048805-A1 | Antilipemic agents | SHIONOGI & CO., LTD. (JP) | 2004-03-11 | — | — | US | claimed |
| US-20040039018-A1 | CETP inhibitors in combination with antihypertensive agents and uses thereof | PFIZER INC. | 2004-02-26 | — | — | US | claimed |
| WO-2004004777-A1 | USE OF CETP INHIBITORS AND ANTIHYPERTENSIVE AGENTS AS WELL AS OPTIONALLY HMG COA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-01-15 | — | — | WO | claimed |
| WO-2004004778-A1 | USE OF CETP INHIBITORS AND OPTIONALLY HMG COA REDUCTABLE INHIBITORS AND/OR ANTIHYPERTENSIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2004-01-15 | — | — | WO | claimed |
| WO-2003094923-A1 | COMBINATION OF AN HMG-CoA REDUCTASE INHIBITOR AND A NITRATE ESTER | SCARAMUZZINO GIOVANNI (IT) | 2003-11-20 | — | — | WO | claimed |
| EP-1358879-A1 | ANTILIPEMIC AGENTS | SHIONOGI & CO., LTD. (JP) | 2003-11-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053842-A1 | Methods of treatment with CETP inhibitors and antihypertensive agents | CETP, APOB, MTTP | HMGCR 9/4885 |
| US-20040248972-A1 | Compounds and uses thereof | HMGCR, PCSK9, CYP46A1 | HMGCR 1/4885 |
| US-20040039018-A1 | CETP inhibitors in combination with antihypertensive agents and uses thereof | CETP, MTTP, APOB | HMGCR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.